Company Overview - EB5 Capital is a leading firm in the EB-5 Visa Program, headquartered in Washington, DC, with a distinguished track record and leadership in the industry [2] - The company has raised over $1 billion of foreign capital across approximately 40 EB-5 projects, attracting investors from over 75 countries [2] - 100% of investors' funds are protected by the Federal Deposit Insurance Corporation (FDIC) insurance prior to deployment into projects [2] Project Milestone - EB5 Capital received the first I-526E approval for its Addison Row (JF32) project, marking a significant milestone in the EB-5 immigration process [1][3] - The approved petition was filed in November 2022 and was pending for 25.6 months [3] - Additional I-526E petition adjudications for the Addison Row project are expected in the near future [1] Addison Row (JF32) Project Details - Addison Row is a 327-unit apartment building in Capitol Heights, Maryland, completed in 2024 with a total development cost of $105.6 million [4] - The project features nearly 400,000 gross square feet, including amenities such as a clubhouse, fitness center, swimming pool, picnic area, dog park, and approximately 500 parking spaces [4] - EB5 Capital raised foreign capital from 52 investors, representing a variety of nationalities, to finance a portion of the capital stack [4]

PORTLAND, Ore., Jan. 14, 2025 /PRNewswire/ -- Portland General Electric Company (NYSE: POR) announced today that it will host an analyst conference call and webcast at 11 a.m. ET on Friday, February 14, to review its fourth quarter and full-year 2024 financial results. Portland General Electric plans to release its fourth quarter and full-year 2024 earnings summary before financial markets open in the United States on February 14.  The conference call will be hosted by Maria Pope, President and CEO; Joe Trp ...

Investors can contact the law firm at no cost to learn more about recovering their lossesLOS ANGELES, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises TransMedics Group, Inc. (“TransMedics” or “the Company”) (NASDAQ: TMDX) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. TransMedics investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to cont ...

ONTARIO, Calif., Jan. 14, 2025 /PRNewswire/ -- Nature's Miracle Holding Inc. (NASDAQ: NMHI) ("Nature's Miracle" or the "Company"), a leader in vertical farming technology and infrastructure, today announced that on January 13, 2025, the Company received written notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist the Company's common stock and warrants from Nasdaq due to the Company's failure to comply with minimum shareholder's ...

Investors can contact the law firm at no cost to learn more about recovering their lossesLOS ANGELES, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Five9, Inc. ("Five9" or the "Company") (NASDAQ: FIVN) investors of a class action representing investors that bought securities between June 4, 2024, and August 8, 2024, inclusive (the "Class Period"). Five9 investors have until February 3, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by p ...

Board of Directors Update - Karen J Wilson appointed to the Board of Directors bringing over three decades of leadership experience in the life sciences sector [1][3] - Steven Mintz departed from the Board of Directors after contributing to the company's transition from private to public [4] POZ Platform Technology - Proprietary POZ technology based on poly(2-oxazoline) polymer enables greater control in drug loading and precision in drug release rate [5] - POZ technology aims to improve pharmacokinetic profiles of drugs with narrow therapeutic windows [5] - Potential applications across a broad range of payloads and indications with ongoing out-licensing and partnership arrangements including a non-exclusive license agreement with Pfizer [6] Company Overview - Clinical-stage biotechnology company developing wholly owned drug product candidates for neurological diseases and other indications [7] - POZ Platform technology has potential to improve efficacy and safety profiles of small molecules RNA-based therapeutics and antibody-based drug conjugates [7] - Headquarters located in Huntsville Alabama on the campus of the HudsonAlpha Institute of Biotechnology [7]

NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DMC Global Inc. (NASDAQ: BOOM) between May 3, 2024 and November 4, 2024, both dates inclusive (the “Class Period”), of the important February 4, 2025 lead plaintiff deadline. SO WHAT: If you purchased DMC Global securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WH ...

HOUSTON, Jan. 14, 2025 (GLOBE NEWSWIRE) -- W&T Offshore, Inc. (NYSE:WTI) ("W&T Offshore" or the "Company") today announced the pricing of its previously announced offering of $350 million in aggregate principal amount of 10.750% senior second lien notes due 2029 (the "Notes") at par in a private offering that is exempt from registration under the Securities Act of 1933, as amended (the "Securities Act"). The closing of the offering of the Notes is expected to occur on January 28, 2025, subject to customary ...

HOUSTON, Jan. 14, 2025 (GLOBE NEWSWIRE) -- W&T Offshore, Inc. (NYSE: WTI) (“W&T Offshore” or the “Company”) today announced the pricing of its previously announced offering of $350 million in aggregate principal amount of 10.750% senior second lien notes due 2029 (the “Notes”) at par in a private offering that is exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). The closing of the offering of the Notes is expected to occur on January 28, 2025, subject to customary ...

Gold Production Overview - The company reported a total gold production of 155,669 ounces in Q4 2024 and 520,293 ounces for the full year 2024, representing a 7% annual growth compared to 2023 [7] - The Lamaque Complex achieved record gold production in Q4 2024, with a 48% increase over Q3 2024, driven by higher ore grade and mill throughput [5] - Kisladag saw a 37% increase in gold production in Q4 2024 compared to Q3 2024, benefiting from two ADR facilities and increased inventory drawdown [8] - Efemcukuru maintained stable production, achieving its annual production guidance for the 10th consecutive year [2] - Olympias experienced lower production in Q4 2024 due to planned equipment downtime and maintenance challenges [6] Operational Highlights by Mine - **Lamaque Complex**: Produced 63,742 ounces in Q4 2024 and 196,538 ounces for the full year 2024, marking a significant increase from 2023 [1][5] - **Kisladag**: Produced 56,483 ounces in Q4 2024 and 174,080 ounces for the full year 2024, showing steady performance and optimization efforts [1][8] - **Efemcukuru**: Produced 19,451 ounces in Q4 2024 and 80,143 ounces for the full year 2024, maintaining consistent output [1][2] - **Olympias**: Produced 15,992 ounces in Q4 2024 and 69,532 ounces for the full year 2024, impacted by operational challenges [1][6] Skouries Project Update - The Skouries project was 82% complete as of December 31, 2024, with Phase 2 at 60% completion [3] - Capital spending for 2024 was approximately $320 million, below the earlier guidance of $350-$380 million, due to delays in ramping up site personnel [3] - A total of $506 million has been invested since the restart of construction in 2023 [3] - A full project update, including revised capital cost estimates and project schedules, is expected in February 2025 [9] Future Plans and Guidance - The company plans to release 2025 guidance and an updated three-year outlook alongside the 2024 full-year results on February 20, 2025 [11] - The Lamaque Complex is expected to reach a milestone of one million ounces poured in Q1 2025 [5] - Kisladag anticipates lower production in Q1 2025 due to seasonal factors and a planned HPGR roll change, with improvements expected in subsequent quarters [8] Financial and Operational Results Call - The company will release its 2024 Year-End and Fourth Quarter Financial and Operational Results on February 20, 2025, followed by a conference call on February 21, 2025 [10]